VERA THERAPEUTICS INC. - CLASS A COMMON STOCK

Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

30 1 2023 05:00:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)

25 1 2023 07:00:01 提供 Nasdaq GlobeNewswire

Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

03 1 2023 15:01:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

20 12 2022 15:05:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics to Present at Upcoming Investor Conferences

22 11 2022 06:30:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP

17 11 2022 06:30:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

09 11 2022 06:30:01 提供 Nasdaq GlobeNewswire

Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney Week 2022 Annual Meeting

05 11 2022 15:50:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2022 Annual Meeting

17 10 2022 06:30:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics to Present at Upcoming Conferences in September 2022

07 9 2022 06:30:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

10 8 2022 06:30:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

04 8 2022 06:30:01 提供 Nasdaq GlobeNewswire

Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

06 7 2022 06:30:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

04 6 2022 13:30:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

02 6 2022 06:30:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress

20 5 2022 15:05:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

16 5 2022 06:30:00 提供 Nasdaq GlobeNewswire

Vera Therapeutics to Present at Upcoming Conferences in May 2022

05 5 2022 15:05:01 提供 Nasdaq GlobeNewswire

Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus

03 5 2022 15:33:34 提供 Nasdaq GlobeNewswire

Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022

02 5 2022 18:06:09 提供 Nasdaq GlobeNewswire